Review
the MET gene for the treatment of non-small-cell
F. Gelsomino, F. Facchinetti, E. Haspinger et al.
· 0 citations
2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Aug 2026
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
RAS alterations mediate resistance to targeted agents in approximately 10% of oncogene-driven lung cancer, and Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.
F. Facchinetti, L. Friboulet, L. Liao et al.
· Annals of Oncology · 0 citations